Error loading player: No playable sources found

Workshop II: Process

Date
January 22, 2024
This product is not available for individual purchase, but it is available as part of the following products:

Session Speakers:


Incorporation of Platform Based Approaches and Prior Knowledge Leveraging Into the Recently Revised ICH Q5A (R2) Guideline

Kathryn KingCDER, FDA


Power of Platform to Accelerate Therapies Beyond a Pandemic 

Ronan Kelly, Eli Lilly and Company 



Leveraging Platforms to Accelerate ADC Formulation and Drug Product Development

Karen Rutherford, Pfizer Inc.


Continuous Platform Improvement to Propel Drug Substance Development,

Heather Nunn, Amgen Inc. 


Related Products

Thumbnail for CASSS Welcome and CMC Strategy Forum 2024 Introductory Comments
CASSS Welcome and CMC Strategy Forum 2024 Introductory Comments
Platform technologies are used extensively across the biopharmaceutical industry to develop drugs efficiently and effectively.  The application of prior knowledge and platforms from established products lays a strong foundation to guide development and advance new medicines to the patients…
Thumbnail for Workshop II: Microbial In-Use Studies and Closed System Transfer Devices
Workshop II: Microbial In-Use Studies and Closed System Transfer Devices
In-Use Studies Microbial Challenge Studies: Cross-Industry Efforts to Harmonize Strategies in Collaboration with Health Authorities
Thumbnail for Workshop I: Analytical
Workshop I: Analytical
PLATFORM TECHNOLOGIES DESIGNATION PROGRAM: HIGHLIGHTS OF STATUTORY LANGUAGE
Thumbnail for Workshop I: Established Best Practices for In-Use Stability Study Design and Testing
Workshop I: Established Best Practices for In-Use Stability Study Design and Testing
HOW TO DESIGN AND PERFORM IN-USE STABILITY AND COMPATIBILITY STUDIES?